Embecta Corp. investors who bought or acquired common stock between Nov. 25, 2025 and May 4, 2026 have until Aug. 17, 2026 to seek appointment as lead plaintiff in a federal securities class action tied to the company's insulin pen needle business. Hagens Berman said the case, filed in the U.S. District Court for the District of New Jersey, alleges Embecta and its management misrepresented the business as "stable," "resilient," and "incredibly resolute" even as the company was losing share at a major customer and facing softer retail-channel volumes while reaffirming guidance. When Embecta reported second-quarter fiscal 2026 results on May 5, 2026, it disclosed revenue had fallen more than 14% against prior guidance of flat to down 2%, cut full-year 2026 adjusted EPS guidance by about 43% at the midpoint and reduced its quarterly dividend 93% to $0.01 from $0.15 per share. The shares fell 57.8% in one trading day, dropping from $9.25 to $3.90, and the firms circulating investor notices say shareholders can still participate in any recovery without serving as lead plaintiff.